. h, B6 mice injected with PARP2KD Py8119 cells developed more bone metastases than control Py8119 cells (n = 15). i, j, Nude mice injected with PARP1KD 1833 cells (i, n = 5) or B6 mice injected with PARP1KD Py8119 cells (j, n = 9) had similar bone metastases as respective control 1833 cells (n = 4) or Py8119 cells (n = 10). k, l, Serum CTX-1 levels in nude mice (k) or B6 mice (l) injected with PARP2KD 1833 cells (n = 4) or Py8119 cells (n = 7) were higher than mice injected with control cells. m, Osteoclast precursors had increased expression of osteoclast marker gene CTSK after co-culturing with Py8119-shPARP2 cells for 3 days as compared to Py8119-shNT or shPARP1 cells (n = 9). n, Py8119-shPARP2 cells had increased RANKL mRNA (left), decreased OPG mRNA (middle) and elevated RANKL/OPG ratio (right) as compared to Py8119-shNT or shPARP1 cells (n = 3). o, A diagram showing that PARP2KD in breast cancer cells increases osteoclast differentiation. p, PARP2 levels negatively correlated with the proliferation rate of 1833 cells (n = 8). q, Migration of PARP2KD 1833 cells through transwell was increased (n = 8). Data represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., non-significant. Two-sided Student's t-test was used to calculate statistical difference. Source data are provided as a Source Data file. . c, Bone metastasis of Py8119 cells was similar in B6 WT or PARP1KO mice (n = 13). d, Bone metastasis of Py8119 cells was similar in B6 WT or PARP1CKO (n = 14) mice. e-g, PARP2KO (e, n = 56) and PARP2 flox/flox (P2F) + MMTV-Cre (f, n = 26), but not P2F + lyzM-Cre (g, n = 44), increased tumor free survival of MMTV-PyMT mice compared with respective control PARP2WT (e, n = 50) or P2F (f, g, n = 45) mice. Two-sided log-rank test was used to calculate statistical difference. h, i, The time of primary tumor growth between tumor onset and end point (maximal volume limit) of mice in e and f was not altered by PARP2 deletion. j-m, Primary mammary tumor growth were similar for PARP2KD 1833 cells vs. control 1833 cells in nude mice (j, n = 5), PARP1KD Py8119 cells vs control Py8119 cells in B6 WT mice (k, n = 13), Py8119 cells in WT vs. PARP2KO B6 mice (l, n = 7), and Py8119 cells in WT vs. PARP1KO mice (m, n = 10). Statistical analysis was performed using two-way ANOVA with Sidak's multiple comparison. n, Left, H&E staining of spontaneous lung metastases in PARP2KO MMTV-PyMT mice (scale bar, 25 μm). Arrows, lung metastases. Right, PARP2KO MMTV-PyMT mice had reduced tumor burden of spontaneous lung metastases compared with WT MMTVPyMT mice (n = 36). o, p, Tumor burden of spontaneous lung metastases was less in B6 mice injected with PARP2KD (o, n = 12) or PARP1KD (p, n = 5) Py8119 cells at mammary fat pad than mice with control cells. Data represent mean ± SEM, *P < 0.05; n.s., nonsignificant. a-d, h, i, Two-sided Student's t-test was used to calculate statistical difference. n-p, Two-sided Mann-Whitney U test was performed (non-normally distributed data). Source data are provided as a Source Data file. , μCT of the tibiae from PARP2KO mice showed reduced BV, Tb.Th, BMD and increased SMI compared with littermate WT control mice (2-month-old, male, n = 6). c, Images of the trabecular bone of the tibial metaphysis (top) (scale bar, 100 μm) and the entire proximal tibia (bottom) (scale bar, 1 mm) from WT or PARP2KO mice. d, Trabecular bone parameters. e, Histomorphometry of TRAP-stained bone sections from the distal femur showed that PARP2KO mice had more osteoclasts than WT mice (2-month-old, male, n = 6). f, PARP2KO cultures showed increased osteoclast differentiation (n = 3). Left, TRAP staining (scale bar, 25 μm); right, TRAP expression. g, Images of the trabecular bone of the tibial metaphysis (top) (scale bar, 100 μm) and the entire proximal tibia (bottom) (scale bar, 1 mm) from WT or PARP1CKO mice. h, μCT of the tibiae showed that PARP1CKO mice had decreased BV, Tb.Th and increased SMI compared with WT littermates (2-month-old, male, n = 6). i, Histomorphometry of the distal femur showed more osteoclasts in PARP1CKO mice than WT littermate controls (2-month-old, male, n = 6). j, PARP1CKO cultures showed increased osteoclast differentiation (n = 3). Left, TRAP staining (scale bar, 25 μm); right, TRAP expression. k, Serum bone formation marker P1NP levels of olaparib treated (n = 8), PARP2KO (n = 11) or PARP1KO (n = 10) mice were lower. Data represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., non-significant. Two-sided Student's t-test was used to calculate statistical difference. Source data are provided as a Source Data file. The expression of osteoclast marker genes (a, n = 3) and RANK gene (b, n = 6 for PARP1KO, n = 3 for PARP2KO) in osteoclast differentiation assay was similarly up-regulated by PARP1KO or PARP2KO. P1, PARP1; P2, PARP2; C, control; R, RANKL; TRAP, tartrate-resistant acid phosphatase; CTSK, cathepsin K; CAR2, carbonic anhydrase 2; Oscar, osteoclast-associated receptor; Calcr, calcitonin receptor; NFATc1, Nuclear factor of activated T-cells, cytoplasmic 1; Rosi, rosiglitazone. c, Cultured PARP2CKO bone marrow cells had~85% PARP2 deletion and RANKL did not alter PARP2 mRNA levels (n = 3). d, PARP2 protein level was reduced by RANKL in cultured WT bone marrow cells. Western blot analyses were repeated twice and showed similar results. e, f, PARP2KO bone marrow cells had complete PARP2 deletion. RANKL did not alter PARP2 mRNA (e, n = 12) but reduced PARP2 protein levels (f). Western blot analyses were repeated twice and showed similar results. g, h, Osteoclast differentiation assay with overexpression of control GFP, PARP2 WT, uncleavable mutants D61E or D187E, or enzymatic activity dead mutant E534A in RAW 264.7 murine macrophage cells. Only D61E mutant suppressed osteoclast differentiation. g, TRAP staining was repeated three times and showed similar results. h, CTSK expression (n = 3). i, A diagram showing osteoclast differentiation. Data represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., non-significant. Two-sided Student's t-test was used to calculate statistical difference. Source data are provided as a Source Data file. . e, RT-qPCR showed that mRNA levels of CCL4, CCL6 and CCL9 were reduced in PARP2CKO IMCs (n = 9) but not in PARP1CKO IMCs (n = 6). f, The expression of CCL4, CCL6 and CCL9 mRNA in IMCs was suppressed by the treatment of 30 μM or 100 μM olaparib (n = 9). g, CCL4 mRNA, but not CCL6 and CCL9 mRNA, was reduced in bone marrow cells of olaparib-treated B6 mice compared with DMSO-treated mice (2-month-old, female, 5-week daily treatment, n = 5). Data represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., non-significant. Two-sided Student's t-test was used to calculate statistical difference. Source data are provided as a Source Data file. . f, g, Neither CCL3 overexpression in Py8119 (f, n = 4) nor CCR1/5 antagonists BX plus MAV (g, n = 6) affected olaparib-induced IMC accumulation in bone marrow. Data represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., non-significant. Two-sided Student's t-test was used to calculate statistical difference. Source data are provided as a Source Data file. showed that H3K4me3 (Histone H3 trimethyl Lys4) level at CCL3 promoter was lower in PARP2CKO IMCs compared with WT control IMCs (n = 3). e, In ChIP, PARP1KD did not alter β-catenin binding to CCL3 promoter in Py8119 cells (n = 3). f, ChIP of p65/NFB showed that both PARP1KD and PARP2KD reduced p65/NFB binding to CCL3 promoter (n = 3). g, TOP/FOP flash assay revealed that PARP1 did not regulate β-catenin transcriptional activity (n = 6). h, Treatment with β-catenin inhibitor PRI-724 eliminated the expression of β-catenin target gene cyclin D1 (n = 3). i, Consensus TCF binding sites CTTTG(A/T)(A/T) identified at human or mouse CCL3 promoter. j, In vitro PARylation assay with recombinant human PARP1, PARP2 and GST-β-catenin with or without olaparib showed no PARylation of β-catenin. Western blot analyses were repeated twice and showed similar results. k, Both anti-RANKL and zoledronate (ZOL) (n = 5) diminished olaparib-induced bone metastasis (n = 10). Data represent mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., non-significant. Two-sided Student's t-test was used to calculate statistical difference. Source data are provided as a Source Data file. 
PARP inhibitor
Physician's Choice Treatment or Placebo Identifier Other Name Cancer types Inhibitor name Fracture Serious bone or musculoskeletal pain Non-serious bone or musculoskeletal pain Osteolysis or Osteonecrosis Fracture Serious bone or musculoskeletal pain Non-serious bone or musculoskeletal pain
Osteolysis or Osteonecrosis
Reference NCT00494234 ICEBERG 1 Breast Olaparib n/a 1/54 (1.85%) 7/54 (12.96%) n/a n/a n/a n/a n/a 1 NCT00494442 ICEBERG 2 / study 9 Ovarian Olaparib 1/57 (1.75%) n/a n/a n/a n/a n/a n/a n/a 2 NCT00679783 study 20 Ovarian/Breast Olaparib n/a n/a 5/90 (5.56%) n/a n/a n/a n/a n/a 5 NCT01078662 study 42
Ovarian/ Breast/ Prostate/ Pancreatic/ Advanced Tumours Olaparib 1/298 (0.34%) n/a 32/298 (10.74%) 1/298 (0.34%) n/a n/a n/a n/a 6 NCT02034916 ABRAZO Breast Talazoparib n/a n/a 9/83 (10.84%) n/a n/a n/a n/a n/a 11 NCT01891344 ARIEL2 Ovarian Rucaparib n/a n/a n/a n/a n/a n/a n/a n/a 12 NCT01968213 ARIEL3 Ovarian Rucaparib 4/372 (1.08%) n/a n/a n/a 2/189 (1.06%) n/a n/a n/a 13 NCT01847274 ENGOT-OV16/NOVA Ovarian Niraparib n/a n/a 20/367 (5.45%) n/a n/a n/a 5/179 (2. Reported data is presented as adverse events / total patient number (event incidence) in the group for PARP inhibitor treatment and the group for Physician's Choice Treatment or Placebo when available. b, Statistic analyses illustrate that patients with PARP inhibitor treatment showed increased incidence of serious bone or musculoskeletal pain and osteolysis/osteonecrosis, as well as an increased risk of bone fracture. The incidence of non-serious bone or musculoskeletal pain are comparable between the two groups of patients. Data represent mean ± SEM. Two-sided Student's t-test was used to calculate statistical difference. n/a, not available. Supplementary Fig. 10 The development of the BLI signal over the entire course in main and Supplementary figures (Suppl. Supplementary Fig. 6d- 
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